Cargando…

Recommendations on the follow‐up of patients with Gaucher disease in Spain: Results from a Delphi survey

Management of Gaucher disease (GD) is challenging due to its wide genotypic and phenotypic variability and changing clinical manifestations due to effective treatment. Sixteen face‐to‐face meetings with experts were held in order to discuss daily clinical practice and identify controversies regardin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giraldo, Pilar, Andrade‐Campos, Marcio, Morales, Montserrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830018/ https://www.ncbi.nlm.nih.gov/pubmed/36636594 http://dx.doi.org/10.1002/jmd2.12342

Ejemplares similares

Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease
por: Giraldo, Pilar, et al.
Publicado: (2021)

Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?
por: Andrade-Campos, Marcio, et al.
Publicado: (2020)

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic
por: Andrade-Campos, Marcio M., et al.
Publicado: (2021)

Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease
por: Valero-Tena, Esther, et al.
Publicado: (2023)

Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher’s disease
por: Roca-Espiau, Mercedes, et al.
Publicado: (2019)

Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease
por: Andrade-Campos, Marcio M., et al.
Publicado: (2020)

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously
por: Noya, MSoledad, et al.
Publicado: (2018)

Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice
por: Louw, Vernon Johan, et al.
Publicado: (2023)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease
por: Andrade-Campos, Marcio, et al.
Publicado: (2017)

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.
por: Serrano-Gonzalo, I., et al.
Publicado: (2022)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula
por: Giraldo, Pilar, et al.
Publicado: (2012)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016)

Diagnosis and follow-up of patients with Hunter syndrome in Spain: A Delphi consensus
por: González-Gutiérrez-Solana, Luis, et al.
Publicado: (2018)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Serum Phospholipid Profile Changes in Gaucher Disease and Parkinson’s Disease
por: López de Frutos, Laura, et al.
Publicado: (2022)

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
por: de Pablos-Velasco, Pedro, et al.
Publicado: (2019)

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease
por: Maas, M., et al.
Publicado: (2008)

Gaucher Disease with Mesenteric Lymphadenopathy: A Case with 13-year Follow-up
por: Ye, Zi-Xing, et al.
Publicado: (2016)

The Influence of Genetic Variability and Proinflammatory Status on the Development of Bone Disease in Patients with Gaucher Disease
por: Gervas-Arruga, Javier, et al.
Publicado: (2015)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease1
por: Hughes, Derralynn, et al.
Publicado: (2007)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
por: Rolfs, Arndt, et al.
Publicado: (2013)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt
por: Abdelwahab, Magy, et al.
Publicado: (2016)

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2019)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

Parkinson disease in Gaucher disease
por: Rodriguez-Porcel, Federico, et al.
Publicado: (2017)

Set of Quality Indicators of Pediatric Intensive Care in Spain: Delphi Method Selection
por: Hernández-Borges, Angel A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f32i84vj4jok1j9pifsl0pp4ga